Rein Therapeutics Inc.
$1.83
0%
2026-04-21 09:11:01
www.reintx.com
NCM: RNTX
Explore Rein Therapeutics Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$51.31 M
Current Price
$1.83
52W High / Low
$2.4 / $1.02
Stock P/E
—
Book Value
$-1.02
Dividend Yield
—
ROCE
-121.99%
ROE
-1.4%
Face Value
—
EPS
$-1.96
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
10
Beta
1.4
Debt / Equity
—
Current Ratio
0.7
Quick Ratio
0.7
Forward P/E
—
Price / Sales
—
Enterprise Value
$83.57 M
EV / EBITDA
-3.81
EV / Revenue
—
Rating
Buy
Target Price
$10
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
Cons
- Capital efficiency is modest.
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | MiMedx Group, Inc. | $3.25 | 10.44 | $507.35 M | — | 22.95% | 21.61% | $7.99 / $3.31 | $1.73 |
| 2. | Immatics N.V. | $11.25 | — | $1.51 B | — | -35.05% | -37.1% | $12.41 / $3.94 | $4.18 |
| 3. | OmniAb, Inc. | $1.55 | — | $237.44 M | — | -24.23% | -23.36% | $2.29 / $1.22 | $1.85 |
| 4. | Arrowhead Pharmaceuticals, Inc. | $71.64 | 46.54 | $10.05 B | — | 8.27% | 75.5% | $76.76 / $10.92 | $4.14 |
| 5. | VivoSim Labs, Inc. | $1.54 | — | $4.02 M | — | -115.61% | -51.07% | $5.3 / $1.25 | $1.7 |
| 6. | Sutro Biopharma, Inc. | $34.58 | — | $572.9 M | — | -106.34% | 435.02% | $34.58 / $5.23 | $-15.43 |
| 7. | Nautilus Biotechnology, Inc. | $2.96 | — | $383.49 M | — | -36.49% | -32.27% | $4.31 / $0.62 | $1.24 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -3.96 M | -5.49 M | -6.87 M | -5.61 M | -5.8 M | — |
| Net Profit | -31.97 M | -5.58 M | -6.82 M | -5.5 M | -40.98 M | — |
| EPS in Rs | -1.14 | -0.2 | -0.24 | -0.2 | -1.46 | -0.27 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -21.93 M | -28.11 M | -15.35 M | -27.65 M |
| Net Profit | -49.87 M | -62.88 M | -15.73 M | -27.33 M |
| EPS in Rs | -1.78 | -2.24 | -0.56 | -0.97 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 24.16 M | 62.19 M | 106.01 M | 22.01 M |
| Total Liabilities | 52.24 M | 52.8 M | 99.12 M | 3.38 M |
| Equity | -28.09 M | 9.39 M | 6.89 M | 18.62 M |
| Current Assets | 4.33 M | 13.66 M | 18.27 M | 21.87 M |
| Current Liabilities | 6.18 M | 5.75 M | 4.38 M | 3.38 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -19.36 M | -22.29 M | -19.81 M | -24.86 M |
| Investing CF | — | 0 M | 16.2 M | 26.46 M |
| Financing CF | 9.76 M | 17.82 M | 15.79 M | 0 M |
| Free CF | -19.36 M | -22.29 M | -19.81 M | -24.86 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -299.71% | 42.43% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2022-11-11 | 1:0.05 |